MPLT · Maplight Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · MPLT
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| R&D | $53.68M | - | $27.09M |
| SG&A | $3.76M | - | $4.08M |
| Total Operating Expenses | $23.54M | - | $31.50M |
| D&A | $162.0K | - | $100.0K |
| Operating Income | ($64.50M) | - | ($31.50M) |
| Interest Expense | - | - | - |
| Income Tax | - | - | - |
| Net Income | ($60.67M) | - | ($19.02M) |
| EPS - Basic | ($29.33) | - | ($37.18) |
| EPS - Diluted | ($29.33) | - | ($25.08) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Cash & Equivalents | $55.71M | $46.73M | $38.25M |
| Accounts Receivable | - | - | - |
| Inventory | - | - | - |
| Accounts Payable | $3.19M | $3.29M | $1.91M |
| Current Assets | $327.23M | $324.67M | $114.60M |
| Total Assets | $418.79M | $479.51M | $257.22M |
| Current Liabilities | $14.28M | $16.23M | $15.92M |
| Long-term Debt | - | - | - |
| Total Liabilities | $18.95M | $21.14M | $23.71M |
| Stockholders' Equity | $399.83M | $458.37M | ($193.63M) |
| Retained Earnings | ($421.19M) | ($360.52M) | ($199.37M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Operating Cash Flow | ($25.55M) | - | - |
| Investing Cash Flow | $37.50M | - | - |
| Financing Cash Flow | ($47.0K) | - | - |
| CapEx | $24.0K | - | - |
| Free Cash Flow | ($25.57M) | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|
| Profitability | |||
| Gross margin | - | - | - |
| Operating margin | - | - | - |
| EBITDA margin | - | - | - |
| Net margin | - | - | - |
| Free cash flow margin | - | - | - |
| FCF / Net income | 0.42 | - | - |
| R&D / Revenue | - | - | - |
| SG&A / Revenue | - | - | - |
| Effective tax rate | - | - | - |
| Return on assets | -14.5% | - | -7.4% |
| Return on equity | -15.2% | - | 9.8% |
| Return on invested capital | - | - | - |
| Liquidity | |||
| Current ratio | 22.91 | 20.01 | 7.20 |
| Quick ratio | 22.91 | 20.01 | 7.20 |
| Cash ratio | 3.90 | 2.88 | 2.40 |
| Leverage | |||
| Debt / Equity | - | - | - |
| Debt / Assets | - | - | - |
| Debt / EBITDA | - | - | - |
| Interest coverage | - | - | - |
| Equity multiplier | 1.05 | 1.05 | -1.33 |
| Liabilities / Assets | 0.05 | 0.04 | 0.09 |
| Efficiency | |||
| Asset turnover | - | - | - |
| Inventory turnover | - | - | - |
| Days sales outstanding | - | - | - |
| Days inventory outstanding | - | - | - |
| Days payable outstanding | - | - | - |
| Cash conversion cycle | - | - | - |
| Valuation | |||
| P / E | - | - | - |
| P / B | 0.0x | - | - |
| P / S | - | - | - |
| EV / EBITDA | - | - | - |
| Growth | |||
| Revenue growth (YoY) | - | - | - |
| Revenue CAGR (3y) | - | - | - |
| Revenue CAGR (5y) | - | - | - |
| Gross profit growth (YoY) | - | - | - |
| Operating income growth (YoY) | - | - | - |
| Net income growth (YoY) | - | - | - |
| EPS growth (YoY) | - | - | - |
| EPS CAGR (3y) | - | - | - |
| EPS CAGR (5y) | - | - | - |
| FCF growth (YoY) | - | - | - |
| FCF CAGR (5y) | - | - | - |
| Book value growth (YoY) | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing MapLight Therapeutics against the 5 most active filers in the same SIC group.